Mel Krajden,Darrel Cook,Naveed Z Janjua
Mel Krajden
In 2016, Canada signed on to the World Health Organization (WHO) 2030 hepatitis C virus (HCV) disease elimination targets. Most of Canada's HCV disease burden is among five disproportionately affected population groups: 1) Baby boomers, who...
Evan Elias,Julia Uhanova,Qian Li et al.
Evan Elias et al.
Background: Intestinal immunity, and immunoglobulin A (IgA) in particular, may play an important role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). The aim of this study was to document the prevalence ...
Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada [0.03%]
加拿大肝病研究协会和加拿大医学微生物学与传染病协会关于乙型肝炎病毒感染管理的2018年指南
Carla S Coffin,Scott K Fung,Fernando Alvarez et al.
Carla S Coffin et al.
Hepatitis B virus (HBV) infection is an important public health problem in Canada. In keeping with evolving evidence and understanding of HBV pathogenesis, the Canadian Association for the Study of Liver Disease periodically publishes HBV m...
The Z-Profile Study: a multicenter, retrospective cohort study to assess the real-world use and effectiveness of elbasvir/grazoprevir in Canadian adult patients with chronic hepatitis C [0.03%]
加拿大成人慢性丙型肝炎患者中艾拉巴斯韦/格拉普韦的实际使用和疗效的多中心回顾性队列研究(Z-_PROFILE研究)
Edward Tam,Julie Tremblay,Chris Fraser et al.
Edward Tam et al.
Background: Canada was the first country to approve elbasvir/grazoprevir (EBR/GZR) for the treatment of chronic HCV infection for genotypes 1 and 4 with or without ribavirin and genotype 3 with sofosbuvir, with no recomme...
Differences among hepatitis C patients seen in community and specialist outpatient care settings [0.03%]
社区和专科门诊就诊的丙型肝炎患者之间的差异
Stefanie Materniak,Samantha Bland,Alyssa Margeson et al.
Stefanie Materniak et al.
Background: In the province of New Brunswick, care for patients infected with hepatitis C is provided in both community-based care settings and specialist-based care settings, but little is known about the differences bet...
Practical management of esophageal varices in the context of SARS-CoV-2 (COVID-19): the Alberta protocol [0.03%]
SARS-CoV-2(COVID-19)背景下的食管静脉曲张实用管理:艾伯塔协议
Stephen E Congly,Matthew D Sadler,Juan G Abraldes et al.
Stephen E Congly et al.
The challenges of managing varices during the COVID-19 pandemic are reviewed, and a treatment algorithm is presented to best manage patients with advanced liver disease during periods of limited access to endoscopy. ...
Sociodemographic risk factors for hepatitis C virus infection in a prospective cohort study of 257 persons in Canada who inject drugs [0.03%]
加拿大一项关于吸毒者的前瞻性队列研究中的丙型肝炎病毒感染的社会人口学风险因素（n=257）
Faustyna Zietara,Pam Crotty,Michael Houghton et al.
Faustyna Zietara et al.
Background: Approximately 60% of incident hepatitis C virus (HCV) infections are due to intravenous drug use; therefore, understanding the socio-demographics of people who inject drugs (PWID) is necessary to achieve HCV e...
Baseline assessment of and linkage to care for newly diagnosed patients with chronic hepatitis B [0.03%]
新诊断慢性乙型肝炎患者的基线评估和接诊治疗链接机制
Tamara Leah Remington,Mariam Osman,Kimberley Simmonds et al.
Tamara Leah Remington et al.
Background: Patients with chronic hepatitis B (CHB) are at risk of complications and require lifelong monitoring. We evaluated the care of newly diagnosed CHB patients. ...
An evaluation of knowledge and concerns in women of child-bearing potential living with chronic hepatitis C infection [0.03%]
慢性丙型肝炎感染育龄女性的知识和关注评估
Holly Hatashita,Curtis Cooper
Holly Hatashita
Background: There is little research focused on women living with the hepatitis C virus (HCV). We evaluated the knowledge, opinions, and concerns of women living with HCV of child-bearing potential. We specifically focuse...
Black Lives Matter: Hepatologists and the duty to oppose systemic and non-systemic racism and bias [0.03%]
黑人的命也是命：肝病学家反对系统性和非系统性种族主义和偏见的职责
Eric M Yoshida,Natasha Chandok
Eric M Yoshida